Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.17.3.2 (xanthine oxidase)
 8,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Urokinase-type plasminogen activator (uPA) and its cell surface receptor (uPAR) have been shown to be expressed in macrophages in atherosclerotic arterial walls, but the regulatory mechanisms of their expression remain unclear. The present study was performed to examine the effects of lysophosphatidylcholine (lysoPC), an important atherogenic lipid, on the expression of uPA and uPAR in human monocyte-derived macrophages. LysoPC upregulated the mRNA expression of uPA and uPAR, and it increased the protein expression of uPA in the culture medium and bound to the cell surface and of uPAR in the particulate fraction of the cells. LysoPC significantly increased the binding of the amino-terminal fragment of uPA to the treated cells and the cell-associated plasminogen activator activity. LysoPC stimulated superoxide anion production and increased intracellular oxidant levels in the cells. The combined incubation with reduced glutathione diethyl ester or N-acetylcysteine, antioxidants, suppressed the upregulation of uPA and uPAR mRNA and the increase in plasminogen activator activity by lysoPC. uPA and uPAR mRNA expression was also induced by the incubation with xanthine and xanthine oxidase, a superoxide anion-generating system. The results suggest that lysoPC increased the expression of uPA and uPAR and their functional activities in human monocyte-derived macrophages, at least in part through a redox-sensitive mechanism. This coordinate increase in the expression of uPA and uPAR in human macrophages by lysoPC could play an important role in plaque formation and disruption, arterial remodeling, and angiogenesis in atherosclerotic arterial walls.
 ...
PMID:Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway. 1063 25

The synthesis and structures of two types of molecules are presented: [MVIO3 - nSn(OSiR2R')]1- (M = Mo, n = 0-3; M = W, n = 3) and [MVIO2(OSiR2R')(bdt)]1- (M = Mo, W; bdt = benzene-1,2-dithiolate). For both types, R2R' are Me3, Pri3, Ph3, Me2But and Ph2But. The complete series of oxo/sulfido/silyloxo molybdenum complexes has been prepared. Complexes with n = 0 are readily prepared by the silylation of Ag2MoO4 and sustain mono- or disulfidation with Ph3SiSH to form a species with n = 1 and n = 2, respectively. Complexes with n = 3 are accessible by the silylation of [MOS3]2-. Structures of the representative series members [MoO3(OSiPh2But)]1-, [MoO2S(OSiPh3)]1-, [MoOS2(OSiPri3)]1-, [MoS3(OSiPh2But)]1-, and also [WS3(OSiMe2But)]1-, all with tetrahedral stereochemistry, are presented. Benzene-1,2-dithiolate complexes are prepared by the reaction of [MoO3(OSiR2R')]1-with the dithiol or by the silylation of previously reported [MO3(bdt)]2-. The structures of [MoO2(OSiPh2But)(bdt)]1- and [WO2(OSiPri3)(bdt)]1- conform to square-pyramidal stereochemistry with an oxo ligand in the apical position. The role of these complexes in the preparation of site analogues of the xanthine oxidoreductase enzyme family is noted. The sulfidation reactions reported here point to the utility of Ph3SiSH and Pri3SiSH as reagents for MoVI-based oxo-for-sulfido conversions.
 ...
PMID:Silylation, sulfidation, and benzene-1,2-dithiolate complexation reactions of oxo- and oxosulfidomolybdates(VI) and -tungstates(VI). 1804 55